OVID Overview

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is4.17 USD with a low forecast of 2.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ovid Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Ovid Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -14.29

Ovid Therapeutics Inc (OVID) has 23 emplpoyees as of May 30 2026.

Today OVID has the market capitalization of 509.53M USD.